Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review

  • ID: 1292009
  • SWOT Analysis
  • 65 pages
  • GlobalData
  • Celgene Corporation
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Johnson & Johnson
  • Novartis AG
  • MORE
Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Feb 15, 2018: Celgene Names John Weiland As Board Director
Jan 30, 2018: NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease
Jan 25, 2018: Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results
Jan 08, 2018: Celgene Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance
Jan 08, 2018: Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Johnson & Johnson
  • Novartis AG
  • MORE
Section 1 - About the Company
  • Celgene Corp - Key Facts
  • Celgene Corp - Key Employees
  • Celgene Corp - Key Employee Biographies
  • Celgene Corp - Major Products and Services
  • Celgene Corp - History
  • Celgene Corp - Company Statement
  • Celgene Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Celgene Corp - Business Description
  • R&D Overview
  • Celgene Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Celgene Corp - Strengths
  • Celgene Corp - Weaknesses
  • Celgene Corp - Opportunities
  • Celgene Corp - Threats
  • Celgene Corp - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Celgene Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jan 30, 2018: NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease
  • Jan 25, 2018: Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results
  • Jan 08, 2018: Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance
  • Jan 08, 2018: Celgene Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance
  • Dec 29, 2017: Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors
  • Dec 05, 2017: Bioethics International Releases the Good Pharma Scorecard in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency
  • Dec 05, 2017: Celgene Launches Celgene Cancer Care Links to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries
  • Nov 21, 2017: Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting
  • Oct 31, 2017: Health2047 Spins Out Health2047 SwitchCo
  • Oct 26, 2017: Celgene Reports Third Quarter 2017 Operating and Financial Results
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Celgene Corp, Key Facts
  • Celgene Corp, Key Employees
  • Celgene Corp, Key Employee Biographies
  • Celgene Corp, Major Products and Services
  • Celgene Corp, History
  • Celgene Corp, Other Locations
  • Celgene Corp, Subsidiaries
  • Celgene Corp, Key Competitors
  • Celgene Corp, Ratios based on current share price
  • Celgene Corp, Annual Ratios
  • Celgene Corp, Annual Ratios
  • Celgene Corp, Annual Ratios
  • Celgene Corp, Interim Ratios
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Celgene Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Celgene Corp, Performance Chart (2013 - 2017)
  • Celgene Corp, Ratio Charts
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Novartis AG
  • Merck & Co Inc
  • Johnson & Johnson
  • Genentech Inc
  • Eli Lilly and Co
  • Eisai Co Ltd
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • AstraZeneca Plc
  • Amgen Inc
  • Abbott Laboratories
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll